Since therapeutic KRAS inhibition has recently been suggested to sensitize pancreatic cancer cells to immune checkpoint inhibitor therapy and clinical evidence from other tumor entities such as malignant melanoma or non-small cell lung cancer point at potential further sensitization to immunotherapy by concomitant irradiation; one might even envision a quadruple approach that also includes immune checkpoint inhibitors in these regimens [60]. Here, KRAS is linked to familial pancreatic carcinoma.